Skip to main content
Premium Trial:

Request an Annual Quote

Linda Avey Versus the New York Times

Over at her blog, Linda Avey, a co-founder of 23andMe who left the company last fall to start an Alzheimer's disease research foundation, is calling out the New York Times' Andrew Pollack. According to Avey, Pollack "has been digging around, looking for dirt and hoping to stir up controversy for a story he's apparently writing about the personal genetics industry." There's no article published yet in the Times – Pollack's newest piece discusses a failed drug trial for an Alzheimer's disease treatment – and Avey doesn't say in her post what Pollack is after. She does, however, admonish Pollack for attacking the "fledgling industry" and says that the goal of 23andMe is "to remove the barriers of access to [genetic] data." Pollack, she writes, could even benefit as these "data-empowered people … may just help lead us into a new age of personalized health." Avey didn't seem to mind the Times' coverage of 23andMe's spit parties, so this has the Daily Scan wondering what Pollack is working on.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.